Total System Services, Inc. (TSS) traded within a range of $53.25 to $53.87 after opening the day at $53.7. The company has seen its stock increase in value by 9.5% so far this year. The stock was up close to 0.19% on light volume in last trading session and closed at $53.69 per share. After the recent gain, the stock is currently holding -4.64% below its 52 week high of $56.54 and 43.78% above its 12-month low of $38.73. The shares are up by over 8.29% in the last three months, and the RSI indicator value of 63.29 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Total System Services, Inc. provides payment processing, merchant, and related payment services to financial and nonfinancial institutions in the United States, Europe, Canada, Mexico, and internationally. It operates through four segments: North America Services, International Services, Merchant Services, and NetSpend. The company offers account processing and output services, including processing the card application, initiating service for the cardholder, processing card transaction for the issuing retailer or financial institution, and accumulating the account’s transactions. It also provides fraud management services to monitor the unauthorized use of accounts; fraud detection systems for identifying fraudulent transactions; and other services, such as customized communication services to cardholders, and information verification services associated with granting credit, debt collection, and customer service. In addition, the company offers processing services, acquiring solutions, related systems, and integrated support services, which include processing various payment forms, such as credit, debit, prepaid, electronic benefit transfer, and electronic check; authorization and capture of transactions; clearing and settlement of transactions; information reporting services related to transactions; merchant billing services; and point-of-sale equipment sales and service. Further, it provides general purpose reloadable prepaid debit cards and payroll cards, as well as alternative financial services to underbanked and other consumers. The company was founded in 1982 and is headquartered in Columbus, Georgia.
Waddell & Reed Financial, Inc. (WDR) continued its upward trend with the stock climbing 2.47% or $0.44 to close the day at $18.25 on light trading volume of 1.29M shares, compared to its three month average trading volume of 1.34M. The Overland Park Kansas 66202 based company has been underperforming the asset management group over the past 52 weeks, with the stock losing -7.49%, compared to the industry which has advanced 34.53% over the same period. With RSI of 45.01, the stock should still continue to rise and get closer to its one year target estimate of $16.79, making it a hold for now.
Waddell & Reed Financial, Inc., through its subsidiaries, provides investment management and advisory, investment product underwriting and distribution, and shareholder services administration to mutual funds, and institutional and separately managed accounts in the United States. The company acts as an investment adviser for institutional and other private investors, and provides sub advisory services to other investment companies; and underwrites and distributes registered open-end mutual fund portfolios. It also offers fee-based asset allocation investment advisory products to advisors channel customers; distributes business partners’ variable annuity products, and retirement and life insurance products to advisors channel customers; and sells life insurance and disability products underwritten by various carriers. The company distributes investment products through its wholesale channel comprising other broker/dealers, various retirement platforms, and registered investment advisors, as well as through independent financial advisors; and markets investment advisory services to institutional investors directly or through consultants. Waddell & Reed Financial, Inc. was founded in 1937 and is based in Overland Park, Kansas.
Depomed, Inc. (DEPO) dropped $-0.12 to close the day at a new closing price of $16.97, a -0.7% decrease in value from its previous closing price that moved the stock 38.53% above its 52 week low of $12.25. A total of 1.28M shares exchanged hands during the day compared with its three month average trading volume of 1.49M. The stock, which fluctuated between $16.94 and $17.39 during the day, currently situated -37.19% below its 52 week high. The stock is down by -10.5% in the past one month and down by -10.73% over the past three months. With a one year target estimate of $23.91 and RSI of 34.19, the stock still has upside potential, making it a hold for now.
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.